Since the identification, in 1996, of the first case of variant Creutzfeldt-Jakob disease (vCJD) in humans various approaches have been implemented and/or proposed to prevent this disease from being transfusion transmitted. In addition, a variety of possible laboratory-based approaches have been developed and will continue to be developed for the vCJD screening of blood donors. Various issues related to the implementation of such vCJD testing is likely to assume greater importance as diagnostic tests for vCJD becomes available for the potential screening of blood donors. The purpose of this Consensus Conference was to bring together international experts in an effort to determine which principles should guide the introduction of such testing. These experts provided the scientific and biological background of bovine spongiform encephalopathy (BSE) and vCJD, an understanding of their current epidemiology, as well as the ethical and legal issues that would impact on the implementation of a screening test for preventing the transfusion transmission of vCJD. This contentious issue is of potential considerable importance to transfusion medicine personnel worldwide, as well as to future recipients of allogeneic blood components.

中文翻译：

---

共识会议的程序：筛查献血者CJD变异体。

自从1996年在人类中发现首例变异型克雅氏病（vCJD）以来，已采取和/或提出了各种方法来防止这种疾病通过输血传播。另外，已经开发了多种可能的基于实验室的方法，并将继续开发用于vCJD筛查献血者的方法。随着针对vCJD的诊断测试可用于献血者的潜在筛查，与实施此类vCJD测试相关的各种问题可能会变得更加重要。这次共识会议的目的是召集国际专家，共同努力确定应采用哪些原则来指导此类测试。这些专家提供了牛海绵状脑病（BSE）和vCJD的科学和生物学背景，对他们当前流行病学的理解以及可能影响防止vCJD输血传播筛查测试实施的道德和法律问题。这个争议性问题对于全球的输血医学人员以及同种异体血液成分的未来接受者而言具有潜在的重要意义。